A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects


    loading  Checking for direct PDF access through Ovid

Abstract

ObjectiveTo determine the effect of multiple subcutaneous doses of recombinant human interleukin (rhuIL)-10 on plasma HIV RNA levels and CD4 T-cell counts, and to evaluate its safety and tolerability in HIV-infected subjects.DesignProspective, randomized, double-blind, placebo-controlled, multicenter trial.SubjectsThirty-nine HIV-infected subjects with CD4 T-cell counts > 200 × 106/l, plasma HIV RNA concentrations ≥ 3.18 log10 copies/ml and on stable antiretroviral therapy were recruited from six centers.InterventionSubjects received (subcutaneously) rhuIL-10 1 μg/kg daily, 4μg/kg daily, 8μg/kg three times per week, placebo daily or placebo three times per week for 4 weeks.Main outcome measuresProspectively defined outcomes included safety and tolerability, plasma HIV RNA levels and CD4 T-cell counts. Outcomes were assessed at baseline, weeks 1, 2, 3 and 4 during treatment and weeks 2 and 4 following completion of therapy.ResultsBaseline characteristics were similar in all groups. Compared to baseline, no significant change in plasma HIV RNA concentrations or CD4 T-cell counts was observed in any of the groups. RhuIL-10 was generally well tolerated. Two patients receiving rhuIL-10 4 μg/kg required discontinuation due to thrombocytopenia. One patient receiving rhuIL-10 4 μg/kg who had chronic hepatitis B and C infections discontinued drug because of elevated liver function tests. One patient receiving placebo discontinued study drug because of depression.ConclusionThe lack of a demonstrable virological benefit, as assessed by plasma viral load, with 4 weeks of rhuIL-10 does not support the development of this immune-based therapy for treatment of HIV infection.

    loading  Loading Related Articles